LOS ANGELES, May 30, 2018 /PRNewswire/ -- CytRx Corporation
(Nasdaq: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that Mr.
John Caloz, Chief Financial Officer,
will present at the 8th Annual LD Micro Invitational
Conference on Tuesday, June 5, 2018
at 1:30 P.M. Pacific Daylight Time at
the Luxe Sunset Boulevard Hotel in Bel-Air.
Mr. Caloz will discuss the LADR™ platform, its broad potential
in treating various tumor types, its advantages over antibody drug
conjugates and an example of a LADR™ surrogate product proof of
concept (aldoxorubicin). He will also address the goal of
obtaining pharmaceutical partnerships to develop the LADR™ pipeline
candidates that are eligible for Investigational New Drug
(IND)-enabling studies. Additionally, Mr. Caloz will discuss
ongoing clinical studies of aldoxorubicin conducted by NantCell,
who owns the worldwide license and IND for the product.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap investment space. What started
out as a newsletter highlighting unique companies has transformed
into several influential conferences annually (Invitational,
Summit, and Main Event). In excess of 1,000 people are expected to
attend the Invitational, to hear presentations from more than 200
leading microcap companies. The company's website, ldmicro.com, is
a portal that provides exclusive intraday information on the entire
sector, including the first pure microcap index (LDMi) which covers
stocks in North America with
market capitalizations between $50-$300M.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company
specializing in research and clinical development of novel
anti-cancer drug candidates that employ linker technologies to
enhance the accumulation and release of drug at the tumor. CytRx is
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug
conjugate, is an improved version of the widely used anti-cancer
drug doxorubicin and has been out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; our ability to develop new ultra-high potency drug
candidates based on our LADR™ technology platform; and other risks
and uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-to-present-at-8th-annual-ld-micro-invitational-conference-300656258.html
SOURCE CytRx Corporation